Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D03ZMX
|
|||
| Drug Name |
Monoaryl-1,2-diamine derivative 3
|
|||
| Synonyms |
PMID29473428-Compound-64
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Company |
GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C23H29F3N4O2S
|
|||
| Canonical SMILES |
CC(C)CN(C1CCCCC1)C2=C(C=C(C=C2)C3CC3C(=O)O)NC4=NC(=NS4)C(F)(F)F
|
|||
| InChI |
1S/C23H29F3N4O2S/c1-13(2)12-30(15-6-4-3-5-7-15)19-9-8-14(16-11-17(16)20(31)32)10-18(19)27-22-28-21(29-33-22)23(24,25)26/h8-10,13,15-17H,3-7,11-12H2,1-2H3,(H,31,32)(H,27,28,29)
|
|||
| InChIKey |
NXZKEHFQEXBLSD-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Indoleamine 2,3-dioxygenase 1 (IDO1) | Target Info | Modulator | [1] |
| Target's Patent Info | Indoleamine 2,3-dioxygenase 1 (IDO1) | Target's Patent Info | [1] | |
| BioCyc | Superpathway of tryptophan utilization | |||
| Tryptophan degradation | ||||
| L-kynurenine degradation | ||||
| Tryptophan degradation to 2-amino-3-carboxymuconate semialdehyde | ||||
| NAD de novo biosynthesis | ||||
| KEGG Pathway | Tryptophan metabolism | |||
| Metabolic pathways | ||||
| African trypanosomiasis | ||||
| NetPath Pathway | TSLP Signaling Pathway | |||
| IL5 Signaling Pathway | ||||
| TGF_beta_Receptor Signaling Pathway | ||||
| Pathwhiz Pathway | Tryptophan Metabolism | |||
| Reactome | Tryptophan catabolism | |||
| WikiPathways | Tryptophan metabolism | |||
| Metabolism of amino acids and derivatives | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.